A Phase II Study of Maintenance With Azacitidine in MDS Patients

Groupe Francophone des Myelodysplasies

Status and phase

Terminated

Phase 2

Conditions

Leukemia, Myelocytic, Acute

Myelodysplastic Syndromes

Treatments

Drug: Azacitidine

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00446303

GFM aza05

Details and patient eligibility

About

A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission (CR or PR) after intensive chemoterapy.

The primary objective is response duration (MDS or AML)

Full description

A academic multicentre study whose aims are to study the benefits of a maintenance therapy with 24 monthly courses af azacytidine in high-risk MDS patients, previously treated with intensive chemotherapy with obtention of a partial or complete response and not eligible for allogeneic transplantation

Enrollment

39 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

MDS with int 2 or high IPSS score eitherRAEB 1 or 2 according to the WHO classification (see appendix 1) or CMML with WBC < 13 109/l RAEB-T according to the FAB classification (see appendix 1) without t(8 ;21), inv 16 or t(16;16) AML secondary to MDS (sAML) with a confirmed MDS phase of at least 2 months with available bone marrow cytogenetics at diagnosis of AML

AND

in CR or PR according to IWG criteria (see appendix 3) after one or two courses of predefined intensive chemotherapy (see page 12) with available cytogenetics at evaluation of response Aged 18 years of age or more Written Informed consent Adequate Contraception, if relevant Negative pregnancy test if relevant. Patients not eligible for the azacitidine confirmatory trial (azacitidine " versus " conventional treatment ") or unwilling to participate to it

Exclusion criteria

AML secondary to myeloproliferative or MDS/MPD WHO subgroups except CMML with WBC< 13 109/l
Therapy related MDS (after chemo or radiotherapy for a previous neoplasm or immune disorder)
Patients eligible for allogeneic bone marrow transplantation (with a identified donor)
Liver and/or kidney failures prohibiting the use of azacitidine. Creatininemia > 1.5 normal value ALAT and ASAT > 3N
Bilirubin > 2 N, unless due to dyserythropoiesis
Known hypersensitivity to azacitidine or mannitol
Other tumor, unstable for the last three years, except in situ uterine carcinoma or basal skin tumor
Uncontrolled infection,
WHO Performance status > 2
Life expectancy less than 3 months